Articles Accepted

Development and Evaluation of Pharmaceutically Equivalent Levosalbutamol Dry Powder Inhaler with Increased In Vitro Deposition.
by Mr. Suraj Laxman Dongare , 19 Aug 2023
Co-Author(s): Minal R. Narkhede,Prachiti S. Rathod

Background: The development and evaluation of an effective and safe dry powder inhaler formulation of levosalbutamol is crucial for optimizing its therapeutic potential in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This abstract presents a comprehensive study on the development and evaluation of a levosalbutamol dry powder inhaler. Objective: The objective of this abstract is to provide an overview of the development process and evaluation outcomes of a levosalbutamol dry powder inhaler, including formulation development, physicochemical characterization, in vitro performance assessment. Methods: This study employed a stepwise approach to develop and evaluate the levosalbutamol dry powder inhaler. Initially, different excipients (Respitose SV010, Respitose ML006, Respitose SV003, Lactohale LH100, Lactohale LH300) and particle size distributions were evaluated to optimize the formulation. Physicochemical characterization, such as particle size, shape, and density, was conducted using appropriate techniques. In vitro performance assessments, including aerodynamic particle size distribution, emitted dose, and fine particle fraction, were determined using validated methods. Results: The formulation development process resulted in an optimized levosalbutamol dry powder inhaler with desirable physicochemical properties, including uniform particle size distribution and suitable density for effective inhalation. In vitro assessments demonstrated favourable aerodynamic characteristics, with a high emitted dose and significant fine particle fraction, indicating efficient lung deposition. Conclusion: The development and evaluation of the levosalbutamol dry powder inhaler exhibited promising results. The optimized formulation demonstrated favourable physicochemical properties, efficient lung deposition, and therapeutic efficacy. These findings support the potential of the levosalbutamol dry powder inhaler as an effective treatment option for respiratory conditions such as asthma and COPD.

Current Issue
Quick Contact